EICHORCondition: Atrial Fibrillation · Stroke · Bleeding · Sponsor: Boston Scientific Corporation
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama Birmingham | Birmingham, Alabama, United States | — |
| Grandview Medical Center | Birmingham, Alabama, United States | — |
| Phoenix Cardiovascular Research Group | Phoenix, Arizona, United States | — |
| HonorHealth Heart Group - Shea | Scottsdale, Arizona, United States | — |
| Tucson Medical Center Healthcare | Tucson, Arizona, United States | — |
| Arrhythmia Research Group | Jonesboro, Arkansas, United States | — |
| Mills Peninsula Health Services | Burlingame, California, United States | — |
| John Muir Medical Center | Concord, California, United States | — |
| Scripps Memorial Hospital | La Jolla, California, United States | — |
| Loma Linda University Medical Center | Loma Linda, California, United States | — |
| St. John's Health Center | Los Angeles, California, United States | — |
| Santa Barbara Cottage Hospital | Santa Barbara, California, United States | — |
+ 74 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06521463